Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Mar 02, 2021 2:39pm
127 Views
Post# 32696791

RE:You may have noticed

RE:You may have noticedIt's a shame we're so cynical about this, even post all the regulatory changes over the years that are supposed to create a more objective and Chinese-wall-protected research opinions.  But I think your description could well hold.  We'll see. 

SPCEO1 wrote: That the moment Ed Nash's report was released was when the stock started to drop in price. I said earlier he may have been holding back his report with its price target hike in order to let the institutions that have been buying complete their buy program. It may simply be, and probably is, coincidence but it sure looks like that is what happened. While Ed's price target increase is nice, it is likely not enough to stimulate a lot of new demand for THTX's stock. It will be interesting to watch the trading volume numbers from now on to see if they dry up a bit. If so, that likely means the institutions who participated in the deal are done topping up their positions. Then we will need copycat institutional investors to join the party if the fun is going to continue. 


<< Previous
Bullboard Posts
Next >>